Pelthos Therapeutics (NYSEAMERICAN:PTHS) Director Ezra Friedberg Sells 558 Shares

Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) Director Ezra Friedberg sold 558 shares of the firm’s stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $26.09, for a total transaction of $14,558.22. Following the sale, the director owned 81,042 shares of the company’s stock, valued at approximately $2,114,385.78. The trade was a 0.68% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Pelthos Therapeutics Trading Up 1.1%

Shares of NYSEAMERICAN PTHS opened at $24.60 on Wednesday. The company has a current ratio of 2.79, a quick ratio of 1.86 and a debt-to-equity ratio of 1.41. The firm’s fifty day moving average price is $26.77. Pelthos Therapeutics Inc. has a 1-year low of $16.09 and a 1-year high of $37.50. The company has a market capitalization of $85.61 million, a price-to-earnings ratio of -1.19 and a beta of 3.10.

Pelthos Therapeutics (NYSEAMERICAN:PTHS) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($3.09) EPS for the quarter. The firm had revenue of $10.91 million during the quarter. Analysts forecast that Pelthos Therapeutics Inc. will post -12.63 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Ikarian Capital LLC increased its position in shares of Pelthos Therapeutics by 309.5% in the fourth quarter. Ikarian Capital LLC now owns 255,758 shares of the company’s stock worth $7,928,000 after purchasing an additional 193,307 shares during the last quarter. Boothbay Fund Management LLC increased its holdings in shares of Pelthos Therapeutics by 279.8% in the 4th quarter. Boothbay Fund Management LLC now owns 80,680 shares of the company’s stock worth $2,501,000 after buying an additional 59,435 shares during the last quarter. J. Goldman & Co LP bought a new stake in shares of Pelthos Therapeutics during the 4th quarter worth $2,418,000. Cantor Fitzgerald L. P. purchased a new position in Pelthos Therapeutics in the fourth quarter worth $1,085,000. Finally, Diadema Partners LP increased its stake in Pelthos Therapeutics by 138.1% in the fourth quarter. Diadema Partners LP now owns 25,000 shares of the company’s stock valued at $775,000 after acquiring an additional 14,502 shares during the last quarter. Hedge funds and other institutional investors own 77.96% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on PTHS. Oppenheimer lifted their price objective on shares of Pelthos Therapeutics from $62.00 to $66.00 and gave the company an “outperform” rating in a research note on Friday, May 15th. Cantor Fitzgerald assumed coverage on Pelthos Therapeutics in a research note on Wednesday, April 1st. They issued an “overweight” rating and a $50.00 target price for the company. Zacks Research upgraded Pelthos Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 24th. Finally, HC Wainwright restated a “buy” rating and issued a $60.00 price objective on shares of Pelthos Therapeutics in a research report on Thursday, March 19th. Five research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $55.80.

Pelthos Therapeutics Company Profile

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).